Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model

BMC Cancer

Magdalena Milczarek²  Mateusz Psurski³  Andrzej Kutner¹  Joanna Wietrzyk² 

[1] Pharmaceutical Research Institute, L. Rydygiera St. 8, Warsaw, 01-793, Poland

[2] Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla St. 12, Wroclaw, 53-114, Poland

[3] Division of Medicinal Chemistry and Microbiology, Wroclaw University of Technology, Wroclaw, Poland

关键词: Colon cancer;    Anticancer activity;    Capecitabine;    5-Fluorouracil;    Combined treatment;    Vitamin D analogs;   

Others  :  1079696
DOI  :  10.1186/1471-2407-13-294

 received in 2013-03-18, accepted in 2013-06-12,  发布年份 2013

【 摘 要 】

Background

Active vitamin D analogs that are less toxic than calcitriol can be useful in the combined treatment of patients suffering from colon cancer. In the present study we demonstrate, for the first time in an in vivo model system, the biological effect of combined therapy using 5-fluorouracil (5-FU) along with vitamin D analog PRI-2191 (tacalcitol, 1,24-dihydroxyvitamin D₃) or PRI-2205 (5,6-trans-isomer of calcipotriol) on colon cancer.

Methods

We investigated the influence of vitamin D analogs on the anticancer activity of 5-FU or capecitabine in the treatment of mice bearing MC38 mouse colon tumors implanted subcutaneously or orthotopically. The cell cycle distribution, E-cadherin expression and caspase 3/7 activity in vitro were also evaluated.

Results

We observed that both PRI-2191 and PRI-2205 significantly enhanced the antitumor activity of 5-FU; but these results depend on the treatment regimen. Applying the optimal schedule of combined therapy we observed a significant decrease in tumor growth, metastasis and also a prolongation of the survival time of mice, in comparison with the administrations of 5-FU given alone. Both combinations indicated a synergistic effect and did not cause toxicity. Moreover, analogs applied after completed course of administration of 5-FU, prolonged the antitumor effect of the drug. Furthermore, when the prodrug of 5-FU, capecitabine, was used, potentiation of its activity was also observed.

Conclusions

Our data suggest that vitamin D analogs (especially PRI-2191) might be potentially applied to clinical use in order to enhance the anticancer effect of 5-FU and also prolong its activity against colon cancer. The activity of PRI-2191 is realized through stopping the cells in the G₀/G₁ cell cycle phase and increasing the expression of E-cadherin.

【 授权许可】

   
2013 Milczarek et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
• [2]Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, et al.: Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005, 97:179-194.
• [3]Giovannucci E: Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostate cancer risk. Nutr Rev 2007, 65:S77-S79.
• [4]Holt PR: New insights into calcium, dairy and colon cancer. World J Gastroenterol 2008, 14:4429-4433.
• [5]Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM, Holick MF: Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 2005, 135:2350-2354.
• [6]Gonzalez-Sancho JM, Larriba MJ, Ordonez-Moran P, Palmer HG, Munoz A: Effects of 1α,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 2006, 26:2669-2681.
• [7]Murillo G, Matusiak D, Benya RV, Mehta RG: Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol 2007, 103:763-767.
• [8]Eelen G, Verlinden L, De CP, Vandewalle M, Bouillon R, Verstuyf A: Vitamin D analogs and coactivators. Anticancer Res 2006, 26:2717-2721.
• [9]Saito T, Okamoto R, Haritunians T, O’Kelly J, Uskokovic M, Maehr H, et al.: Novel Gemini vitamin D3 analogs have potent antitumor activity. J Steroid Biochem Mol Biol 2008, 112:151-156.
• [10]Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL: A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999, 5:1339-1345.
• [11]Chodynski M, Wietrzyk J, Marcinkowska E, Opolski A, Szelejewski W, Kutner A: Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D2. (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners. Steroids 2002, 67:789-798.
• [12]Wietrzyk J, Chodynski M, Fitak H, Wojdat E, Kutner A, Opolski A: Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs 2007, 18:447-457.
• [13]Opolski A, Wietrzyk J, Siwinska A, Marcinkowska E, Chrobak A, Radzikowski C, et al.: Biological activity in vitro of side-chain modified analogues of calcitriol. Curr Pharm Des 2000, 6:755-765.
• [14]Wietrzyk J, Milczarek M, Kutner A: The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics. Oncol Res 2007, 16:517-525.
• [15]Wietrzyk J, Nevozhay D, Filip B, Milczarek M, Kutner A: The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res 2007, 27:3387-3398.
• [16]Wietrzyk J, Nevozhay D, Milczarek M, Filip B, Kutner A: Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol 2008, 62:787-797.
• [17]Pelczynska M, Switalska M, Maciejewska M, Jaroszewicz I, Kutner A, Opolski A: Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer Res 2006, 26:2701-2705.
• [18]Opolski A, Wietrzyk J, Chrobak A, Marcinkowska E, Wojdat E, Kutner A, et al.: Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines. Anticancer Res 1999, 19:5217-5222.
• [19]Wietrzyk J, Pelczynska M, Madej J, Dzimira S, Kusnierczyk H, Kutner A, et al.: Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids 2004, 69:629-635.
• [20]Milczarek M, Rosinska S, Psurski M, Maciejewska M, Kutner A, Wietrzyk J: Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res 2013, 33:433-444.
• [21]Grem JL: Mechanisms of action and modulation of fluorouracil. Semin Radiat Oncol 1997, 7:249-259.
• [22]Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
• [23]Wang X, Chen W, Singh N, Promkan M, Liu G: Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells. Int J Oncol 2010, 36:1573-1580.
• [24]Liu G, Hu X, Chakrabarty S: Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer 2010, 126:631-639.
• [25]Pajtasz-Piasecka E, Szyda A, Rossowska J, Krawczenko A, Indrova M, Grabarczyk P, et al.: Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha) 2004, 50:7-14.
• [26]Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP: Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000, 87:227-253.
• [27]Ekici OD, Li ZZ, Campbell AJ, James KE, Asgian JL, Mikolajczyk J, et al.: Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10. J Med Chem 2006, 49:5728-5749.
• [28]Turna A, Pekcolaklar A, Metin M, Yaylim I, Gurses A: The effect of season of operation on the survival of patients with resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2012, 14:151-155.
• [29]Peters GJ, Backus HH, Freemantle S, van TB, Codacci-Pisanelli G, van der Wilt CL, et al.: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002, 1587:194-205.
• [30]Koren R, Wacksberg S, Weitsman GE, Ravid A: Calcitriol sensitizes colon cancer cells to H2O2-induced cytotoxicity while inhibiting caspase activation. J Steroid Biochem Mol Biol 2006, 101:151-160.
• [31]Bhagavathula N, Hanosh AW, Nerusu KC, Appelman H, Chakrabarty S, Varani J: Regulation of E-cadherin and beta-catenin by Ca2+ in colon carcinoma is dependent on calcium-sensing receptor expression and function. Int J Cancer 2007, 121:1455-1462.
• [32]Chakrabarty S, Radjendirane V, Appelman H, Varani J: Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of β-catenin/TCF activation. Cancer Res 2003, 63:67-71.
• [33]Chakrabarty S, Wang H, Canaff L, Hendy GN, Appelman H, Varani J: Calcium sensing receptor in human colon carcinoma: interaction with Ca2+ and 1,25-dihydroxyvitamin D3. Cancer Res 2005, 65:493-498.
• [34]Ding J, Zhang Z, Pan Y, Liao G, Zeng L, Chen S: Expression and significance of twist, E-cadherin, and N-cadherin in gastrointestinal stromal tumors. Dig Dis Sci 2012, 57:2318-2324.
• [35]Wietrzyk J, Filip B, Milczarek M, Kłopotowska D, Maciejewska M, Dabrowska K, et al.: The influence of 1,25-dihydroxyvitamin D3 and 1,24-dihydroxyvitamin D3 on αvβ3 integrin expression in cancer cell lines. Oncol Rep 2008, 20:941-952.
• [36]Ma Y, Trump DL, Johnson CS: Vitamin D in combination cancer treatment. J Cancer 2010, 1:101-107.
• [37]Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL: Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001, 7:1043-1051.
• [38]Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, et al.: Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 1991, 51:2848-2853.
• [39]Siwinska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, et al.: Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res 2001, 21:1925-1929.
• [40]Kulkarni AD, van Ginkel PR, Darjatmoko SR, Lindstrom MJ, Albert DM: Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. Br J Ophthalmol 2009, 93:1105-1108.
• [41]Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, et al.: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009, 249:420-425.
• [42]Mocellin S: Vitamin D and cancer: deciphering the truth. Biochim Biophys Acta 1816, 2011:172-178.
• [43]Krishnan AV, Trump DL, Johnson CS, Feldman D: The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am 2012, 38:161-178.
• [44]Raimondi S, Johansson H, Maisonneuve P, Gandini S: Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.